31
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      COVID-19 Associated Vertebral Osteomyelitis Caused by Aspergillus Species—A Case Series

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Coronavirus Disease (COVID-19) associated fungal infections including pulmonary aspergillosis, mucormycosis and other invasive fungal infections have been increasingly described in the current pandemic. Aspergillus osteomyelitis is a rare clinical form of aspergillosis. Most cases of Aspergillus osteomyelitis are reported in immunocompromised patients. We describe four cases of vertebral osteomyelitis caused by Aspergillus species in the post COVID-19 setting. To the best of our knowledge, Aspergillus vertebral osteomyelitis has not been described in the post COVID-19 setting. None of the four patients described in this series were immunocompromised and all of them had received steroids during their hospitalization for COVID-19 pneumonitis. Vertebral osteomyelitis caused by Aspergillus species is a rare clinical manifestation of Aspergillosis. It requires a high index of suspicion and prompt efforts to establish a diagnosis. For a clinician involved in assessing a patient with Spondylodiscitis, the work up must not be limited to testing for Tuberculosis. Every attempt must be made to establish the microbiological diagnosis. Combined medical and surgical management is generally needed for Aspergillus osteomyelitis.

          Related collections

          Most cited references6

          • Record: found
          • Abstract: found
          • Article: not found

          Multicenter Epidemiologic Study of Coronavirus Disease–Associated Mucormycosis, India

          During September–December 2020, we conducted a multicenter retrospective study across India to evaluate epidemiology and outcomes among cases of coronavirus disease (COVID-19)–associated mucormycosis (CAM). Among 287 mucormycosis patients, 187 (65.2%) had CAM; CAM prevalence was 0.27% among hospitalized COVID-19 patients. We noted a 2.1-fold rise in mucormycosis during the study period compared with September–December 2019. Uncontrolled diabetes mellitus was the most common underlying disease among CAM and non-CAM patients. COVID-19 was the only underlying disease in 32.6% of CAM patients. COVID-19–related hypoxemia and improper glucocorticoid use independently were associated with CAM. The mucormycosis case-fatality rate at 12 weeks was 45.7% but was similar for CAM and non-CAM patients. Age, rhino-orbital-cerebral involvement, and intensive care unit admission were associated with increased mortality rates; sequential antifungal drug treatment improved mucormycosis survival. The COVID-19 pandemic has led to increases in mucormycosis in India, partly from inappropriate glucocorticoid use.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Aspergillus osteomyelitis: epidemiology, clinical manifestations, management, and outcome.

            The epidemiology, pathogenesis, diagnosis, and management of Aspergillus osteomyelitis are not well understood. Protocol-defined cases of Aspergillus osteomyelitis published in the English literature were reviewed for comorbidities, microbiology, mechanisms of infection, clinical manifestations, radiological findings, inflammatory biomarkers, antifungal therapy, and outcome. Among 180 evaluable patients, 127 (71%) were males. Possible predisposing medical conditions in 103 (57%) included pharmacological immunosuppression, primary immunodeficiency, and neutropenia. Seventy-three others (41%) had prior open fracture, trauma or surgery. Eighty (44%) followed a hematogenous mechanism, 58 (32%) contiguous infections, and 42 (23%) direct inoculation. Aspergillus osteomyelitis was the first manifestation of aspergillosis in 77%. Pain and tenderness were present in 80%. The most frequently infected sites were vertebrae (46%), cranium (23%), ribs (16%), and long bones (13%). Patients with vertebral Aspergillus osteomyelitis had more previous orthopedic surgery (19% vs 0%; P = 0.02), while those with cranial osteomyelitis had more diabetes mellitus (32% vs 8%; P = 0.002) and prior head/neck surgery (12% vs 0%; P = 0.02). Radiologic findings included osteolysis, soft-tissue extension, and uptake on T2-weighted images. Vertebral body Aspergillus osteomyelitis was complicated by spinal-cord compression in 47% and neurological deficits in 41%. Forty-four patients (24%) received only antifungal therapy, while 121 (67%) were managed with surgery and antifungal therapy. Overall mortality was 25%. Median duration of therapy was 90 days (range, 10-772 days). There were fewer relapses in patients managed with surgery plus antifungal therapy in comparison to those managed with antifungal therapy alone (8% vs 30%; P = 0.006). Aspergillus osteomyelitis is a debilitating infection affecting both immunocompromised and immunocompetent patients. The most common sites are vertebrae, ribs, and cranium. Based upon this comprehensive review, management of Aspergillus osteomyelitis optimally includes antifungal therapy and selective surgery to avoid relapse and to achieve a complete response. Copyright © 2013 The British Infection Association. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Osteomyelitis caused by Aspergillus species: a review of 310 reported cases.

              Aspergillus osteomyelitis is a rare infection. We reviewed 310 individual cases reported in the literature from 1936 to 2013. The median age of patients was 43 years (range, 0-86 years), and 59% were males. Comorbidities associated with this infection included chronic granulomatous disease (19%), haematological malignancies (11%), transplantation (11%), diabetes (6%), pulmonary disease (4%), steroid therapy (4%), and human immunodeficiency virus infection (4%). Sites of infection included the spine (49%), base of the skull, paranasal sinuses and jaw (18%), ribs (9%), long bones (9%), sternum (5%), and chest wall (4%). The most common infecting species were Aspergillus fumigatus (55%), Aspergillus flavus (12%), and Aspergillus nidulans (7%). Sixty-two per cent of the individual cases were treated with a combination of an antifungal regimen and surgery. Amphotericin B was the antifungal drug most commonly used, followed by itraconazole and voriconazole. Several combination or sequential therapies were also used experimentally. The overall crude mortality rate was 25%.
                Bookmark

                Author and article information

                Contributors
                pprayag100@gmail.com
                Journal
                Indian J Orthop
                Indian J Orthop
                Indian Journal of Orthopaedics
                Springer India (New Delhi )
                0019-5413
                1998-3727
                15 April 2022
                : 1-9
                Affiliations
                [1 ]GRID grid.410870.a, ISNI 0000 0004 1805 2300, Department of Infectious Diseases, , Deenanath Mangeshkar Hospital, ; Pune, India
                [2 ]GRID grid.410870.a, ISNI 0000 0004 1805 2300, Department of Microbiology, , Deenanath Mangeshkar Hospital, ; Pune, India
                [3 ]GRID grid.410870.a, ISNI 0000 0004 1805 2300, Department of Orthopedics, , Deenanath Mangeshkar Hospital, ; Pune, India
                [4 ]GRID grid.411681.b, ISNI 0000 0004 0503 0903, Bharati Vidyapeeth Deemed University College of Medicine, ; Pune, India
                [5 ]GRID grid.410870.a, ISNI 0000 0004 1805 2300, Department of In-House Research, , Deenanath Mangeshkar Hospital, ; Pune, India
                Author information
                http://orcid.org/0000-0003-2102-7627
                Article
                633
                10.1007/s43465-022-00633-4
                9010711
                a024e79e-5697-4556-9e41-a04fbc612e86
                © Indian Orthopaedics Association 2022

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 18 November 2021
                : 24 March 2022
                Categories
                Case Report

                Orthopedics
                asergillus vertebral osteomyelitis,post covid
                Orthopedics
                asergillus vertebral osteomyelitis, post covid

                Comments

                Comment on this article